Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2017 2
2019 5
2020 4
2021 7
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Integrin adjunct therapy for melanoma.
Andarawewa KL, Moissoglu K, Sup Lee C, Ando Y, Yu M, Debnath P, Shannon JD, Sirinivasan S, Conaway MR, Weber MJ, Schwartz MA. Andarawewa KL, et al. Among authors: ando y. Pigment Cell Melanoma Res. 2015 Jan;28(1):114-6. doi: 10.1111/pcmr.12320. Epub 2014 Nov 3. Pigment Cell Melanoma Res. 2015. PMID: 25264294 Free PMC article. No abstract available.
CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation.
Trac N, Chen LY, Zhang A, Liao CP, Poon C, Wang J, Ando Y, Joo J, Garri C, Shen K, Kani K, Gross ME, Chung EJ. Trac N, et al. Among authors: ando y. J Control Release. 2021 Jan 10;329:614-623. doi: 10.1016/j.jconrel.2020.09.054. Epub 2020 Oct 1. J Control Release. 2021. PMID: 33011241 Free PMC article.
Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
Ando Y, Siegler EL, Ta HP, Cinay GE, Zhou H, Gorrell KA, Au H, Jarvis BM, Wang P, Shen K. Ando Y, et al. Adv Healthc Mater. 2019 Mar;8(5):e1900001. doi: 10.1002/adhm.201900001. Epub 2019 Feb 8. Adv Healthc Mater. 2019. PMID: 30734529 Free PMC article.
A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.
Sandberg ML, Wang X, Martin AD, Nampe DP, Gabrelow GB, Li CZ, McElvain ME, Lee WH, Shafaattalab S, Martire S, Fisher FA, Ando Y, Liu E, Ju D, Wong LM, Xu H, Kamb A. Sandberg ML, et al. Among authors: ando y. Sci Transl Med. 2022 Mar 2;14(634):eabm0306. doi: 10.1126/scitranslmed.abm0306. Epub 2022 Mar 2. Sci Transl Med. 2022. PMID: 35235342
19 results